Needham Initiates Coverage On Arcellx with Buy Rating, Announces Price Target of $31
Needham analyst Gil Blum initiates coverage on Arcellx (NASDAQ:ACLX) with a Buy rating and announces Price Target of $31.
Canaccord Genuity Initiates Coverage On Arcellx with Buy Rating, Announces Price Target of $32
Canaccord Genuity analyst John Newman initiates coverage on Arcellx (NASDAQ:ACLX) with a Buy rating and announces Price Target of $32.
63 Biggest Movers From Yesterday
Gainers
Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the Greek State for the IPCEI Green HiPo project.
Mid-Afternoon Market Update: Dow Dips 900 Points; AC Immune Shares Slide
U.S. stocks traded lower toward the end of trading, after the Federal Reserve raised fed funds rates by 0.75% to a new target range of between 1.5% and 1.75% on Wednesday.
Mid-Day Market Update: Dow Tumbles 700 points; Advent Technologies Shares Spike Higher
U.S. stocks traded lower midway through trading, after the Federal Reserve raised fed funds rates by 0.75% to a new target range of between 1.5% and 1.75% on Wednesday.
37 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Advent Technologies Holdings, Inc. (NYSE: ADN) shares jumped 153% to $2.94 after the company announced it received notification of euro 782.1 million of funding from the Greek State for the IPCEI Green HiPo project.
The Daily Biotech Pulse: Roche’s Alzheimer’s Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours:
82 Biggest Movers From Yesterday
Gainers
Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday.